Thumbnail

亚太黑色素瘤诊断和治疗市场——按癌症类型和地理划分(2020 - 2025 年)

Looking to buy the report?

2015 年亚太地区黑色素瘤诊断和治疗市场价值 5.32 亿美元,预计到 2021 年将达到 11.72 亿美元。

亚太黑色素瘤诊断和治疗市场-市场动态

由于黑色素瘤患病率的增加和医疗保健设施的改善,黑色素瘤诊断和治疗市场正在以显着的速度增长。该报告详细介绍了推动和抑制市场的各种因素,其中一些因素如下所列。

驱动程序

  • 黑色素瘤病例增加
  • 高价产品的批准和接受
  • 有效的免疫疗法 
  • 将当前疗法标记为新设置
  • 政府举措
  • 技术进步

约束

  • 一些发展中地区缺乏认识
  • 与治疗相关的高成本
  • 经济危机
  • 监管问题 

黑色素瘤诊断和治疗市场可以根据癌症类型、癌症阶段、诊断、治疗和地理位置进行细分。根据癌症类型,市场分为浅表性、结节性、恶性雀斑样痣、肢端雀斑样痣和无色素黑色素瘤。根据癌症阶段,市场分为 0 期、I 期、II 期、III 期和 IV 期。根据诊断,市场细分为皮肤镜检查、前哨淋巴结活检、X 射线、血液检查、CT 扫描和超声波。黑色素瘤的治疗分为早期黑色素瘤治疗(切除和莫氏手术)和晚期黑色素瘤治疗(化学疗法、生物疗法、靶向疗法、放射疗法、靶向疗法、免疫疗法、淋巴结切除术)。在地理的基础上,

亚太国家,即日本、中国和印度,预计将成为增长最快的黑色素瘤诊断和治疗市场。

​ 市场上的一些主要参与者是:                                                                  

  • 阿斯利康                                               
  • 百时美施贵宝                                              
  • 礼来公司                                           
  • 葛兰素史克
  • 罗氏      

报告提供了什么

  • 市场定义以及市场关键驱动因素和限制因素的识别。
  • 在全球和区域范围内进行区域特定评估和竞争分析的市场分析。
  • 确定有助于改变市场情景、增加潜在机会的因素以及确定可以在全球和区域范围内影响市场的关键公司。
  • 广泛研究的竞争格局部分以及主要公司的概况
IES 以及他们的战略举措和市场份额。
  • 识别和分析在全球和区域范围内影响行业的宏观和微观因素。
  • 关键市场参与者的综合列表以及对其当前战略利益和关键财务信息的分析。
    • 除了提供的机会外,行业顾问、制造商和其他相关方和相关方的理想资料来源,可以深入了解推动和限制市场的因素。

    1. Introduction                                                 

                    1.1 Report description                                  

                    1.2 Research methodology                                         

    2. Executive summary                                                  

    3. Market overview                                                       

                    3.1 Market definition                                    

                    3.2 Market drivers                                          

                                    3.2.1 Increasing incidences of melanoma cases                 

                                    3.2.2 The approval and uptake of premium-priced products                        

                                    3.2.3 Effective immunotherapies                             

                                    3.2.4 Label extension of current therapies into the new settings                               

                                    3.2.5 Government initiatives                      

                    3.3 Market restraints                                     

                                    3.3.1 Lack of awareness in some developing regions                       

                                    3.3.2 High cost associated with the therapy                         

                                    3.3.3 Economic crisis                      

                                    3.3.4 Regulatory issues                 

                    3.4 Market opportunities                                          

                    3.5 Market threats                                         

    4. Porter’s five force analysis                                                    

                    4.1 Bargaining power of suppliers                                            

                    4.2 Bargaining power of buyers                                

                    4.3 Degree of competition                                          

                    4.4 Threat of substitution                                            

                    4.5 Threat of new entrants                                         

    5. Market segmentation                                                              

                    5.1 By cancer type                                         

                                    5.1.1 Superficial spreading melanoma                    

                                    5.1.2 Nodular melanoma                             

                                    5.1.3 Lentigno maligna melanoma                           

                                    5.1.4 Acral lentiginous melanoma                            

                                    5.1.5 Amelanotic melanoma                       

                                    5.1.6 Others                      

                                                    5.1.6.1 Cutaneous malignant melanoma               

                                                    5.1.6.2 Melanoma of vulva          

                                                    5.1.6.3 Vaginal melanoma or melanoma of black passage             

                    5.2 By cancer stage                                        

                                    5.2.1 Stage 0                      

                                    5.2.1 Stage I                       

                                    5.2.1 Stage II                     

                                    5.2.1 Stage III                    

                                    5.2.1 Stage IV                    

                    5.3 By diagnosis                                               

                                    5.3.1 Dermatoscopy                       

                                    5.3.2 Sentinel lymph node biopsy                            

                                    5.3.3 Blood Tests                             

                                    5.3.4 X-rays                        

                                    5.3.5 Ultrasound                              

                                    5.3.6 CT Scan                     

                    5.4 By treatment                                           

                                    5.4.1 For early melanoma                            

                                                    5.4.1.1 Surgery 

                                                                    5.4.1.1.1 Excision

                                                                    5.4.1.1.2 Mohs surgery

                                    5.4.2 For advanced melanoma                  

                                                    5.4.2.1 Chemotherapy  

                                                    5.4.2.2 Biological therapy             

                                                    5.4.2.3 Radiotherapy     

                                                    5.4.2.4 Targeted therapy            

                                                    5.4.2.5 Immune therapy              

                                                    5.4.2.6 Surgery 

                                                                    5.4.2.6.1 Lymphadenectomy

                    5.5 By geography                                           

                                    5.5.1 Asia-Pacific          

                                                    5.5.1.1 India       

                                                    5.5.1.2 China     

                                                    5.5.1.3 Japan     

                                                    5.5.1.4 Singapore            

                                                    5.5.1.5 Rest of Asia-Pacific           

    6. Competitive landscape                                                           

    7. Company profiles                                                       

                    7.1 Abbott Diagnostics                                  

                    7.2 Agilent Technologies                                              

                    7.3 Roche                                           

                    7.4 GlaxoSmithKline                                       

                    7.5 AstraZeneca                                               

                    7.6 Bristol-Myers Squibb                                              

                    7.7 Eli Lilly                                           

                    7.8 Merck                                           

                    7.9 Novartis                                       

                    7.10 Pfizer                                          

                    7.11 Sanofi                                         

                    7.12 Qiagen N.V. Company                                         

                    7.13 Teva Pharmaceuticals                                          

    8. Appendix                                                       

                    8.1 Abbreviations                                             

                    8.3 Bibliography                                               

                    8.4 Disclaimer              

    Looking to buy the report?

    Need a report that reflects how COVID-19 has impacted this market and its growth?

    Looking to customize report?

    Email

    Message

    By submitting, you confirm that you agree to our privacy policy